TY - JOUR
T1 - Comprehensive Analysis of Anticoagulant Therapy in Patients with Isolated Atrial Flutter
AU - Ardashev, Andrey
AU - Passman, Rod
AU - Zotova, Irina
AU - Efimov, Igor
AU - Rytkin, Eric
AU - Trachiotis, Gregory
AU - Knight, Bradley P.
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/11/1
Y1 - 2024/11/1
N2 - Limited comparative data exist regarding the risk of cardiogenic emboli in patients with isolated atrial flutter (AFL). Some studies suggest a lower complication risk in AFL compared to atrial fibrillation (AFib), but methodological limitations and conflicting reports necessitate a comprehensive investigation. Our analysis proposes that isolated AFL carries a lower risk of ischemic events and left atrial thrombus formation than AFib. Importantly, we caution against applying stroke risk assessment approaches designed for AFib to AFL patients, as it may lead to harmful overestimations and unnecessary anticoagulant prescriptions. Furthermore, we highlight the current lack of sufficient data to determine the overall clinical benefit of prolonged anticoagulant therapy in patients with isolated AFL, especially when CHA2DS2-VASc index values are below 4. This review challenges existing perceptions, offering insights into the nuanced risk profiles of the transitional nature of isolated AFL due to the high incidence of AFib development within a year of AFL diagnosis. In conclusion, tailored risk assessments and further research are essential for precise clinical decision-making in this dynamic landscape.
AB - Limited comparative data exist regarding the risk of cardiogenic emboli in patients with isolated atrial flutter (AFL). Some studies suggest a lower complication risk in AFL compared to atrial fibrillation (AFib), but methodological limitations and conflicting reports necessitate a comprehensive investigation. Our analysis proposes that isolated AFL carries a lower risk of ischemic events and left atrial thrombus formation than AFib. Importantly, we caution against applying stroke risk assessment approaches designed for AFib to AFL patients, as it may lead to harmful overestimations and unnecessary anticoagulant prescriptions. Furthermore, we highlight the current lack of sufficient data to determine the overall clinical benefit of prolonged anticoagulant therapy in patients with isolated AFL, especially when CHA2DS2-VASc index values are below 4. This review challenges existing perceptions, offering insights into the nuanced risk profiles of the transitional nature of isolated AFL due to the high incidence of AFib development within a year of AFL diagnosis. In conclusion, tailored risk assessments and further research are essential for precise clinical decision-making in this dynamic landscape.
UR - http://www.scopus.com/inward/record.url?scp=85204716208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85204716208&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2024.07.031
DO - 10.1016/j.amjcard.2024.07.031
M3 - Article
C2 - 39089525
AN - SCOPUS:85204716208
SN - 0002-9149
VL - 230
SP - 72
EP - 81
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -